IL2 and cancer: CUE Biopharma developed Immuno-Selective Targeting and Alteration of T cells (Immuno-STATs), which were originally designed to prime and expand naïve and pre-existing anti-cancer T cell repertoires by co-delivering an engineered IL-2 variant (IL-2v) [52].